Cypherpunk Technologies Appoints Zcash Founder Zooko Wilcox as Strategic Advisor
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 09 2025
0mins
Source: PRnewswire
- Strategic Advisor Appointment: Cypherpunk Technologies has appointed Zooko Wilcox, the founder of Zcash, as a Strategic Advisor, leveraging his extensive experience in privacy-preserving protocols to provide expert guidance on the future of self-sovereign digital systems, thereby enhancing the company's competitive edge in digital asset governance.
- Investment in Privacy Technology: Zooko emphasized Cypherpunk's commitment to ZEC, indicating that user-controlled privacy is fundamental to a healthy society, and the company's investment represents a strong belief in the principle of economic freedom, which is expected to attract more investors focused on privacy technologies.
- Long-term Value Creation: Following a $58.88 million private placement, Cypherpunk plans to build long-term shareholder value by acquiring ZEC and supporting the development of Zcash, further solidifying its position in the privacy technology market.
- Global Privacy Ecosystem: Cypherpunk is assembling a world-class team of cryptographers and technologists aimed at advancing Zcash and the global privacy ecosystem, a strategy that will enhance the company's influence in the rapidly evolving digital asset market.
Analyst Views on CYPH
About CYPH
Cypherpunk Technologies Inc., formerly Leap Therapeutics, Inc., is engaged in developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The Company focuses on the development of sirexatamab and FL-501 to treat patients with cancer. Zcash is a privacy-preserving blockchains, launched as a fork of Bitcoin with advanced cryptography that enables selective transparency. Zcash has introduced privacy technology through the use of zero-knowledge proofs (zk-SNARKs), allowing transactions to be verified without revealing sender, receiver, or amount. FL-501 is a potential class antibody designed to neutralize GDF-15 and prevent the binding to its receptor. sirexatamab (DKN-01), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. Sirexatamab is being developed in patients with esophagogastric, gynecologic, and colorectal cancers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
